

Zuranolone bests placebo in postpartum depression

June 30 2021



For women with postpartum depression, zuranolone improves symptoms

of depression, as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D-17) score, according to a study published online June 30 in *JAMA Psychiatry*.

Kristina M. Deligiannidis, M.D., from Zucker Hillside Hospital in Glen Oaks, New York, and colleagues conducted a randomized, outpatient trial involving women aged 18 to 45 years, no more than six months postpartum, with postpartum [depression](#) and a baseline HAM-D-17 score of 26 or higher. Participants were randomly assigned to either placebo or zuranolone administered orally each evening for two weeks (76 and 77 participants, respectively).

The researchers observed a significant day-15 improvement in HAM-D-17 score from baseline with zuranolone versus placebo (−17.8 versus −13.6; difference, −4.2). From day three through 45, sustained differences in HAM-D-17 scores favoring zuranolone were observed (differences, −2.7 and −4.1, respectively). At day 15, there were sustained differences favoring zuranolone for HAM-D-17 response (odds ratio, 2.63), HAM-D-17 score remission (odds ratio, 2.53), change from baseline for Montgomery-Åsberg Depression Rating Scale score (difference, −4.6), and Hamilton Rating Scale for Anxiety score (difference, −3.9). One patient in each group experienced a serious adverse event. Due to an adverse event, one patient in the zuranolone group and none in the [placebo group](#) discontinued treatment.

"These encouraging results are an important step in efforts to develop a novel treatment option for patients who suffer from this prevalent condition," Deligiannidis said in a statement.

Several authors disclosed financial ties to [pharmaceutical companies](#), including Sage Therapeutics, which manufactures zuranolone and funded the study. One author reports a patent pending for use of neuroactive steroids in the treatment of [postpartum depression](#).

More information: [Abstract/Full Text](#)

Copyright © 2021 [HealthDay](#). All rights reserved.

Citation: Zuranolone bests placebo in postpartum depression (2021, June 30) retrieved 18 July 2023 from <https://medicalxpress.com/news/2021-06-zuranolone-bests-placebo-postpartum-depression.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.